מתוך medicontext.co.il
LONDON (Reuters Health) – The European Medicines Evaluation Agency on Friday said that its scientific committee has recommended Pfizer's anti-fungal drug voriconazole (Vfend) to treat invasive aspergillosis and invasive infections due to Candida, Scedosporium and Fusarium species. Voriconazole is a new triazole derivative with broad anti-fungal activity.
"The clinical benefits of Vfend are primarily related to results from a study in invasive Aspergillus infections, where survival benefits compared to standard therapy with amphotericin B were noted. In invasive Candida infections, benefits were found in patients infected by fluconazole-resistant strains," the EMEA said in a statement.
The drug should be administered primarily to immunocompromised patients with progressive, possibly life-threatening infections, it added.
The product was recommended for approval on October 4 by the US Food and Drug Administration's Antiviral Drug Products Advisory Committee for aspergillosis infections, but not for patients with persistent fever and low white blood cell counts who are at risk for serious fungal infections.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!